The use of treosulfan and gemcitabine in the treatment of platinum-resistant ovarian cancer

Hilman,S.; Koh,PK.; Collins,S.; Allerton,R.

doi:10.3892/ol_00000038

January-February 2010 Volume 1 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-February 2010 Volume 1 Issue 1

Full Size Image

Article

The use of treosulfan and gemcitabine in the treatment of platinum-resistant ovarian cancer

Authors:
- S. Hilman
- PK. Koh
- S. Collins
- R. Allerton
View Affiliations / Copyright

Affiliations: Weston General Hospital, Somerset, UK. serena.hilman@waht.swest.nhs.uk
Pages: 209-213
|
Published online on: January 1, 2010

https://doi.org/10.3892/ol_00000038
Expand metrics +

Abstract

The combination of treosulfan and gemcitabine (TG) has been shown to have activity in ovarian cancer. These two agents are thought to be synergistic, with gemcitabine causing the persistence of treosulfan-induced DNA crosslinks. This study aimed to investigate the response rates, survival and toxicity in patients with platinum-resistant ovarian cancer treated with TG. A retrospective case note review of the patients treated with TG was performed in one cancer centre between May 1st, 2000 and November 1st, 2005. Estimates of cumulative survival were obtained using the Kaplan-Meier method. Forty-nine patients were identified; median age at diagnosis was 55 years (range, 31-72) and the median follow-up was 45.1 months (range, 12.2-118.3). TG was used as second-, third-, fourth- and fifth-line chemotherapy in 15, 19, 13 and 2 patients, respectively. Fifteen patients (30.6%) had stable disease; 25 (51%), a partial response; 1 (2%), a complete response and 8 (16.3%) had progressive disease. Median survival following diagnosis was 45.1 months and the median relapse-free survival was 12 months. The median survival time from the start of TG was 13.7 months with a relapse-free survival of 6.3 months. The median number of cycles given was 7. The most common toxicity recorded was myelosuppression. There were no treatment-related deaths. TG chemotherapy produced favourable response rates in a heavily pre-treated group of patients with platinum-resistant epithelial ovarian cancer. This doublet warrants further investigation in a phase III trial setting.

View Figures

View References

1	UK ovarian cancer statistics. 2008, Cancer Research UK website.
2	De Vita. Treosulfan and gemcitabine in heavily pretreated patients with breast and ovarian cancer: laboratory study and clinical pilot trial of the ISCO clinical study group. 7th edition. pp. 13642005
3	Fennelly J: Treosulfan (Dihydroxybusulphan) in the management of ovarian carcinoma. Br J Obstet Gynecol. 84:300–303. 1977. View Article : Google Scholar : PubMed/NCBI
4	Corrie PG, Shaw J, Spanswick VJ, et al: Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. Br J Cancer. 92:1997–2003. 2005. View Article : Google Scholar : PubMed/NCBI
5	Kurbacher CM, Grecu OM, Stier U, et al: ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials. Recent Results. Cancer Res. 161:221–230. 2003.PubMed/NCBI
6	Reed NS, Poole CJ, Coleman R, et al: A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG). Eur J Cancer. 42:179–185. 2006. View Article : Google Scholar : PubMed/NCBI
7	Lorusso D, di Stefano A, Fanfani F and Scambia G: Role of gemcitabine in ovarian cancer treatment. Ann Oncol. 17:188–194. 2006. View Article : Google Scholar
8	Grecu OM, Kurbacher CM, Mallman P, Bruckner HW and Cree IA: Treosulfan and gemcitabine in heavily pre-treated patients with breast and ovarian cancer. Proc Am Soc Clin Oncol. 20:abs. 2500. 2001.
9	Paclitaxel, pegylated liposomal doxorubicin and topotecan in the treatment of advanced ovarian cancer, relapsed disease. NICE guidance. 2005
10	Gordon AN, Tonda M, Sun S and Rackoff W: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 95:1–8. 2004. View Article : Google Scholar
11	Peng LH, Chen X and Wu T: Topotecan for ovarian cancer. Cochrane Database Syst Rev. Apr 16;2008.E-pub ahead of print.
12	Breidenbach M, Rein DT, Schondorf T, Schmidt T, Konig E, Valter M and Kurbacher CM: Hematological side-effect profiles of individualised chemotherapy regimen for recurrent ovarian cancer. Anticancer Drugs. 14:341–346. 2003. View Article : Google Scholar : PubMed/NCBI
13	Pederson-Bjergaard J, Nissen NI, Sorensen HM, et al: Acute non-lymphocytic leukaemia in patients with ovarian cancer following long-term treatment with treosulfan (dihydroxybusulfan). Cancer. 45:19–29. 1980. View Article : Google Scholar : PubMed/NCBI
14	Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 25:5180–5186. 2007. View Article : Google Scholar
15	Garcia AA, Hirte H, Fleming G, et al: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago and Princess Margaret Hospital phase II consortia. J Clin Oncol. 26:76–82. 2008. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

The use of treosulfan and gemcitabine in the treatment of platinum-resistant ovarian cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles